TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SSY Group ( (HK:2005) ) just unveiled an announcement.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of its Benidipine Hydrochloride Tablets, used for treating primary hypertension and angina pectoris. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing stakeholders with new opportunities in the pharmaceutical sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company’s primary products include medications for treating conditions such as hypertension and angina pectoris, with a market focus on drug consistency and regulatory compliance.
YTD Price Performance: -12.59%
Average Trading Volume: 14,041,804
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.91B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.